Immunai, a New York-based biotech company, raised $215M in Series B funding, increasing the company’s total funding to date to $295M.
The Series B was led by Koch Disruptive Technologies, with participation from Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, and more, including previous investors.
The company intends to use the funds to expand its “drug actuary” platform for target validation and evaluation.
Led by Noam Solomon, PhD, CEO and co-founder, and Luis Voloch, CTO and co-founder, Immunai uses single-cell genomics and machine learning to discover and develop novel therapeutics that reprogram the immune system. The team of 120 employees, 70 of whom are PhDs or MDs, is composed of experts in genomics, machine learning, bioinformatics, immunology, and software engineering. The company has more than 30 partnerships with Fortune 100 pharmaceutical companies and leading academic institutions, including Harvard, Stanford, Memorial Sloan Kettering, and Baylor College of Medicine.
Headquartered in New York City, with offices in San Francisco, Tel Aviv, Zurich, Prague, and San Francisco, the company has leveraged its proprietary technologies and more than 25 academic partnerships to build AMICATM, the Annotated Multiomic Immune Cell Atlas, a large data atlas of clinically-annotated single-cell immune data. This atlas, combined with its team of immunologists and computational biologists, provides insights into underlying biology that drives disease etiology, allowing the company and its partners to discover novel targets as well as analyze and develop existing pipeline compounds.
In conjunction with the funding, Eli Groner, Managing Director at Koch Disruptive Technologies, will be joining Immunai’s board of directors. The funding follows Immunai’s acquisition of Nebion and the addition of scientists and engineers, including Robert Langer, ScD, to the Board of Directors, Jacques Banchereau, PhD, as Chief Science Officer, and Mark Jacobstein as Chief Business Officer.